Aldeyra Therapeutics Inc.
| NASDAQ: ALDX | Healthcare / Biotechnology / USA |
| 11.02 | +0.1200 | +1.10% | Vol 429.86K | 1Y Perf 297.10% |
| Apr 20th, 2021 16:00 DELAYED |
| BID | 10.81 | ASK | 11.69 | ||
| Open | 10.90 | Previous Close | 10.90 | ||
| Pre-Market | - | After-Market | 11.02 | ||
| - - | - -% |
| Target Price | 24.67 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 123.87 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 523.93M | Earnings Rating | Buy | |
| Price Range Ratio 52W % | 70.30 | Earnings Date | 6th May 2021 |
Today's Price Range 10.8011.27 | 52W Range 2.5014.62 | 5 Year PE Ratio Range -4.50-3.90 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -6.21% | ||
| 1 Month | -8.01% | ||
| 3 Months | -6.53% | ||
| 6 Months | 55.21% | ||
| 1 Year | 297.10% | ||
| 3 Years | 57.43% | ||
| 5 Years | 88.38% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -74.75 | |||
ROE last 12 Months | -67.15 | |||
ROA (5Y Avg) | -45.80 | |||
ROA last 12 Months | -45.36 | |||
ROC (5Y Avg) | -67.37 | |||
ROC last 12 Months | -50.80 | |||
Return on invested Capital Q | -13.62 | |||
Return on invested Capital Y | -52.24 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -10.10 | ||||
| 9.01 | ||||
| - | ||||
| - | ||||
| -24.20 | ||||
| -1.10 | ||||
| 9.01 | ||||
| 1.25 | ||||
| 473.76M | ||||
| Forward PE | -8.61 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 6.30 | ||||
| 6.70 | ||||
| 0.16 | ||||
| 0.26 | ||||
| -19.00 | ||||
| Leverage Ratio | 1.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.26 | -0.35 | -34.62 |
| Q03 2020 | -0.28 | -0.23 | 17.86 |
| Q02 2020 | -0.34 | -0.25 | 26.47 |
| Q01 2020 | -0.48 | -0.34 | 29.17 |
| Q04 2019 | -0.68 | -0.47 | 30.88 |
| Q03 2019 | -0.53 | -0.69 | -30.19 |
| Q02 2019 | -0.51 | -0.49 | 3.92 |
| Q01 2019 | -0.41 | -0.39 | 4.88 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.29 | 12.12 | Positive |
| 6/2021 QR | -0.31 | 13.89 | Positive |
| 12/2021 FY | -1.22 | 2.40 | Positive |
| 12/2022 FY | -1.31 | -13.91 | Negative |
| Next Report Date | 6th May 2021 |
| Estimated EPS Next Report | -0.29 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 429.86K |
| Shares Outstanding | 47.54M |
| Trades Count | 4.64K |
| Dollar Volume | 7.72M |
| Avg. Volume | 1.09M |
| Avg. Weekly Volume | 519.97K |
| Avg. Monthly Volume | 565.36K |
| Avg. Quarterly Volume | 858.60K |
Aldeyra Therapeutics Inc. (NASDAQ: ALDX) stock closed at 11.02 per share at the end of the most recent trading day (a 1.1% change compared to the prior day closing price) with a volume of 429.86K shares and market capitalization of 523.93M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 11 people. Aldeyra Therapeutics Inc. CEO is Todd C. Brady.
The one-year performance of Aldeyra Therapeutics Inc. stock is 297.1%, while year-to-date (YTD) performance is 60.64%. ALDX stock has a five-year performance of 88.38%. Its 52-week range is between 2.5 and 14.62, which gives ALDX stock a 52-week price range ratio of 70.30%
Aldeyra Therapeutics Inc. currently has a PE ratio of -10.10, a price-to-book (PB) ratio of 9.01, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -45.36%, a ROC of -50.80% and a ROE of -67.15%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Aldeyra Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.29 for the next earnings report. Aldeyra Therapeutics Inc.’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Aldeyra Therapeutics Inc. is Strong Buy (1), with a target price of $24.67, which is +123.87% compared to the current price. The earnings rating for Aldeyra Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aldeyra Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aldeyra Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.49, ATR14 : 0.98, CCI20 : -76.41, Chaikin Money Flow : -0.16, MACD : -0.09, Money Flow Index : 54.46, ROC : -8.25, RSI : 42.22, STOCH (14,3) : 24.12, STOCH RSI : 0.00, UO : 44.61, Williams %R : -75.88), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aldeyra Therapeutics Inc. in the last 12-months were:
Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye diseases, allergic conjunctivities, noninfectious anterior uveitis, and Sjogren-Larsson Syndrome. The company is also developing other product candidates for proliferative vitreoretinopathy and other retinal disease, post-transplant lymphoproloferative disease, autoimmune disease, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.
CEO: Todd C. Brady
Telephone: +1 781 761-4904
Address: 131 Hartwell Avenue, Lexington 02421, MA, US
Number of employees: 11
